FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social
PALO ALTO, Calif., Feb. 28 � Today, Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) has approved Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release Capsules for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adults.
Related Bookmarks
- Signature Smiles Dental
- Signature Smiles Dental offers best oral bone graft surgery in Bristol, PA
- IV therapy Pasadena
- Simple Tips to Stay Fit through Ayurveda
- Best Bridal Makeup Services for Women and Men in Bhubaneswar
- The Best Ladies Beauty Parlor in Bhubaneswar
- Vaso Meditech in Chennai
- Abdominoplasty cost in hyderabad | Dr. Dushyanth Kalva
- Buy Indian Spices Online UK
- online dietary supplements for stress
Recent Profiles
Site Works
Banglabetco
Scarborough Shannon
Fun88
Burnette Byrd
Blum Morrison
Graversen Kruse
Outzen Browne
Doherty Holcomb
Heide Mason